Whole-Exome Sequencing Explored Mechanism of Selpercatinib Resistance in RET-Rearranged Lung Adenocarcinoma Transformation Into Small-Cell Lung Cancer: a Case Report
Source : https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-023-02799-5
Small cell transformation was one mechanism by which EGFR-mutation NSCLC acquired resistance after tyrosine kinase inhibitors (TKIs) treatment. A few reports of small cell transformation occurred in other oncogene-driven lung...
KIF5B-RET fusion was still detected in tissues after small cell transformation, and there was no significant change in mutation abundance. The persistence of fusion led researchers to believe that NSCLC transformed into SCLC in this case rather than the histologically NSCLC mixed SCLC component.
Pulmonary Injury After Radioactive Iodine Therapy in Pediatric Papillary Thyroid Cancer: a Case Report
Source : https://pubmed.ncbi.nlm.nih.gov/37956658/
This patient's pulmonary condition is consistent with radiation-induced pulmonary injury including development of pulmonary fibrosis. With the availability of RET fusion targeted inhibitors, this case highlights a rare pulmonary side...
With the availability of RET fusion targeted inhibitors, this case highlights a rare pulmonary side effect of radioactive iodine for clinicians to recognize.
Comprehensive Molecular Analysis Identifies RET Alterations Association With Response of ICIs in Multi-Immunotherapy Cohorts
Source : https://www.sciencedirect.com/science/article/abs/pii/S1567576923016089?via=ihub
The RET gene, which is frequently mutated across many types of cancer, has been proven to be critically involved in tumorigenesis and tumour developme...
Asian researchers identified an association between RET mutations and enhanced tumor inflamed antitumor immune response and enhanced tumor antigenicity, which led to an elevated response rate and prolonged OS and PFS among patients treated with immune checkpoint inhibitors.
Revolutionizing Cancer Drug Development: Harnessing the Potential of Basket Trials
Source : https://pubmed.ncbi.nlm.nih.gov/37934000/
The landscape of cancer therapy has been transformed by advances in clinical next-generation sequencing, genomically targeted therapies, and immunotherapies.
Administration approval for uncommon molecular alterations (eg, NTRK fusions, BRAF mutations, RET/FGFR1 alterations) are discussed.
Sustained Clinical Response to 4th-Line Therapy with Selpercatinib in RET Fusion-Positive Combined Small Cell Lung Cancer
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693826/
Combined small cell lung cancer (C-SCLC) is a relatively rare subtype of small cell lung cancer (SCLC) which combines SCLC and any component of non-small cell carcinoma (NSCLC).
This report presents a patient with stage IV C-SCLC harboring the KIF5B-RET fusion whose disease responded to selpercatinib for both primary tumor and intrapulmonary metastases in fourth-line treatment, highlighting the importance of comprehensive molecular testing in C-SCLC for selecting the optimal treatment.